Congo red and protein aggregation in neurodegenerative diseases

Brain Research Reviews

Volumn 53, Issue 1, 2007, Pages 135-160

  Frid, Petrea ^a   Anisimov, Sergey V ^a   Popovic, Natalija ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; Complement; Congo red; Glycosaminoglycan; Huntington's disease; Imaging probe; Inclusion; Microglia; Parkinson's disease; Prion disease; Protein configuration

Indexed keywords

1 BROMO 2,5 BIS(3 HYDROXYCARBONYL 4 HYDROXY)STYRYLBENZENE; 1 BROMO 2,5 BIS(4 HYDROXYSTYRYL)BENZENE; 1 FLUORO 2,5 BIS(3 HYDROXYCARBONYL 4 HYDROXY)STYRYLBENZENE; 1 IODO 2,5 BIS(3 HYDROXYCARBONYL 4 HYDROXYL)STYRYLBENZENE; 1 IODO 2,5 BIS(3 HYDROXYCARBONYL 4 METHOXY)STYRYLBENZENE; 1,4 BIS(3 CARBOXY 4 HYDROXYPHENYLETHENYL)BENZENE; ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; BENZENE DERIVATIVE; BENZIDINE; BENZOPURPURIN 4B; CHICAGO SKY BLUE; CHRYSAMINE G; CONGO RED; CYSTAMINE; DEXTRAN SULFATE; DIRECT FAST YELLOW; DIRECT RED 75; DIRECT RED 80; DYE; EVANS BLUE; FK 506 BINDING PROTEIN; GLYCOSAMINOGLYCAN; HEMAGGLUTININ; K 114; PENTOSAN POLYSULFATE; POLYGLUTAMINE; PRION PROTEIN; TRYPAN BLUE; VORINOSTAT; X 34;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANOPHTHALMIA; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BETA SHEET; BLOOD BRAIN BARRIER; BOLUS INJECTION; CHANNEL GATING; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; CONCENTRATION RESPONSE; DEGENERATIVE DISEASE; DISEASE MODEL; DOSE RESPONSE; DRUG CARCINOGENICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG UPTAKE; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUNTINGTON CHOREA; HYDROCEPHALUS; HYDRONEPHROSIS; IC 50; IMMUNE RESPONSE; INFLUENZA VIRUS; LETHAL DOSE; MICROPHTHALMIA; MOLECULAR SIZE; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PREVALENCE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; RAUSCHER LEUKEMIA VIRUS; REVIEW; SCRAPIE; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME;

AMYLOID BETA-PROTEIN; ANIMALS; COLORING AGENTS; CONGO RED; HUMANS; INCLUSION BODIES; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PROTEIN FOLDING; SENILE PLAQUES; STAINING AND LABELING;

EID: 33845192482     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2006.08.001     Document Type: Review

References (214)

1. Abe K., Kato M., and Saito H. Congo red reverses amyloid beta protein-induced cellular stress in astrocytes. Neurosci. Res. 29 (1997) 129-134
2. Agrawal N., Pallos J., Slepko N., Apostol B.L., Bodai L., Chang L.-W., Chiang A.-S., Thompson L.M., and Marsh J.L. Identification of combinatorial drug regimens for treatment of Huntingtonís disease using Drosophila. Proc Natl. Acad. Sci. U. S. A. 102 (2005) 3777-3781
3. Alder H., and Reimann F. Beitrag zur Funktionsprüfung des retikuloendothelialen Apparates. Z. Exp. Med. 47 (1925) 617-633
4. Alvarez A., Opazo C., Alarcon R., Garrido J., and Inestrosa N.C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272 (1997) 348-361
5. Ando Y. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Amyloid. Suppl. 1 (2003) 55-66
6. Ando Y., Haraoka K., Terazaki H., Tanoue Y., Ishikawa K., Katsuragi S., Nakamura M., Sun X., Nakagawa K., Sasamoto K., Takesako K., Ishizaki T., Sasaki Y., and Doh-ura K. A novel tool for detecting amyloid deposits in systemic amyloidosis in vitro and in vivo. Lab. Invest. 83 (2003) 1751-1759
7. Apostol B.L., Kazantsev A., Raffioni S., Illes K., Pallos J., Bodai L., Slepko N., Bear J.E., Gertler F.B., Hersch S., Housman D.E., and Marsh J.L. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5950-5955
8. Arispe N., Rojas E., and Pollard H.B. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 567-571
9. Arispe N., Pollard H.B., and Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10573-10577
10. Arrasate M., Mitra S., Schweltzer E.S., Segal M.R., and Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
11. Azimova R.K., and Kagan B.L. Ion channels formed by a fragment of alpha-synuclein (NAC) in lipid membranes. Biophys. J. 84 (2003) 53a
12. Balzarini J., Mitsuya H., De Clercq E., and Broder S. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). Int. J. Cancer 37 (1986) 451-457
13. Barrow C.J., Yasuda A., Kenny P.T., and Zagorski M.G. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J. Mol. Biol. 225 (1992) 1075-1093
14. Becht H., and Drzeniek R. The effect of azo dyes on myxovirus neuraminidase and on virus multiplication. J. Gen. Virol. 2 (1968) 261-268
15. Blättler T., Brandner S., Raeber A.J., Klein M.A., Voigtlander T., Weissmann C., and Aguzzi A. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 389 (1997) 69-73
16. Beaudoin A.R. The teratogenicity of Congo red in rats. Proc. Soc. Exp. Biol. Med. 117 (1964) 176-179
17. Beekes M., McBride P.A., and Baldauf E. Cerebral targeting indicates vagal spread of infection in hamsters fed with scrapie. J. Gen. Virol. 79 (1998) 601-607
18. Bennhold H. Über die Ausscheidung intravenös einverleibten Kongorotes bei den verschiedensten Erkrankungen insbesondere bei Amyloidosis. Dtsch. Arch. Klin. Med. 142 (1923) 32-46
19. Beringue V., Adjou K.T., Lamoury F., Maignien T., Deslys J.P., Race R., and Dormont D. Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J. Virol. 74 (2000) 5432-5440
20. Bodner R.A., Outeiro T.F., Altmann S., Maxwell M.M., Cho S.H., Hyman B.T., McLean P.J., Young A.B., Housman D.E., and Kazantsev A.G. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4246-4251
21. Borchelt D.R., Taraboulos A., and Prusiner S.B. Evidence for synthesis of scrapie prion protein in the endocytic pathway. J. Biol. Chem. 267 (1992) 16188-16199
22. Bose M., Gestwicki J.E., Devasthali V., Crabtree G.R., and Graef I.A. "Nature-inspired" drug-protein complexes as inhibitors of Abeta aggregation. Biochem. Soc. Trans. 33 (2005) 543-547
23. Bradfield J.W., and Born G.V. Lymphocytosis produced by heparin and other sulphated polysaccharides in mice and rats. Cell. Immunol. 14 (1974) 22-32
24. Brinkworth R.I., and Fairlie D.P. Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates. Biochem. Biophys. Res. Commun. 188 (1992) 624-630
25. Brown D.R., Schmidt B., and Kretzschmar H.A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 380 (1996) 345-347
26. Brown D.R., Schulz-Schaeffer W.J., Schmidt B., and Kretzschmar H.A. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp. Neurol. 146 (1997) 104-112
27. Burgevin M.C., Passat M., Daniel N., Capet M., and Doble A. Congo red protects against toxicity of β-amyloid peptides on rat hippocampal neurons. NeuroReport 5 (1994) 2429-2432
28. Campana V., Sarnataro D., and Zurzolo C. The highways and byways of prion protein trafficking. Trends Cell Biol. 15 (2005) 102-111
29. Carter D.B., and Chou K.C. A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol. Aging 19 (1998) 37-40
30. Caspi S., Halimi M., Yanai A., Sasson S.B., Taraboulos A., and Gabizon R. The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem. 273 (1998) 3484-3489
31. Caughey B., and Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Ann. Rev. Neurosci. 26 (2003) 267-298
32. Caughey B., and Race R.E. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J. Neurochem. 59 (1992) 768-771
33. Caughey B., and Race R.E. Scrapie-associated PrP accumulation and its inhibition: revisiting the amyloid-glycosaminoglycan connection. Ann. N. Y. Acad. Sci. 724 (1994) 290-295
34. Caughey B., and Raymond G.J. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J. Biol. Chem. 266 (1991) 18217-18223
35. Caughey B., and Raymond G.J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67 (1993) 643-650
36. Caughey B., Race R.E., Ernst D., Buchmeier M.J., and Chesebro B. Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J. Virol. 63 (1989) 175-181
37. Caughey B.W., Dong A., Bhat K.S., Ernst D., Hayes S.F., and Caughey W.S. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30 (1991) 7672-7680
38. Caughey B., Raymond G.J., Ernst D., and Race R.E. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. 65 (1991) 6597-6603
39. Caughey B., Ernst D., and Race R.E. Congo red inhibition of scrapie agent replication. J. Virol. 67 (1993) 6270-6272
40. Caughey B., Brown K., Raymond G.J., Katzenstein G.E., and Thresher W. Binding of the protease-sensitive form of prion protein PrP to sulfated glycosaminoglycan and Congo red. J. Virol. 68 (1994) 2135-2141
41. 2 nanoparticles. Exp. Cell Res. 305 (2005) 51-62
42. Clarke M.C., and Kimberlin R.H. Pathogenesis of mouse scrapie: distribution of agent in the pulp and stroma of infected spleens. Vet. Microbiol. 9 (1984) 215-225
43. Cooper J.H. Selective amyloid staining as a function of amyloid composition and structure. Histochemical analysis of the alkaline Congo red, standardized toluidine blue, and iodine methods. Lab. Invest. 31 (1974) 232-238
44. Cohen A.S., and Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183 (1959) 1202-1203
45. Cohlberg J.A., Li J., Uversky V.N., and Fink A.L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 41 (2002) 1502-1511
46. Crowther D.C., Kinghorn K.J., Miranda E., Page R., Curry J.A., Duthie F.A., Gubb D.C., and Lomas D.A. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 132 (2005) 123-135
47. Crystal A.S., Giasson B.I., Crowe A., Kung M.P., Zhuang Z.P., Trojanowski J.Q., and Lee V.M. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem. 86 (2003) 1359-1368
48. De Gioia L., Selvaggini C., Ghibaudi E., Diomede L., Bugiani O., Forloni G., Tagliavini F., and Salmona M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem. 269 (1994) 7859-7862
49. DeLellis R.A., Glenner G.G., and Ram J.S. Histochemical observations on amyloid with reference to polarization microscopy. J. Histochem. Cytochem. 16 (1968) 663-665
50. Demaimay R., Harper J., Gordon H., Weaver D., Chesebro B., and Caughey B. Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J. Neurochem. 71 (1998) 2534-2541
51. Demaimay R., Chesebro B., and Caughey B. Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo red analogs. Arch. Virol., Suppl. 16 (2000) 277-283
52. Dezutter N.A., Dom R.J., de Groot T.J., Bormans G.M., and Verbruggen A.M. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. Eur. J. Nucl. Med. 26 (1999) 1392-1399
53. Diamantstein T., Wagner B., Beyse I., Odenwald M.V., and Schulz G. Stimulation of humoral antibody formation by polyanions: II. The influence of sulfate esters of polymers on the immune response in mice. Eur. J. Immunol. 1 (1971) 340-343
54. Diaz-Hernandez M., Moreno-Herrero F., Gomez-Ramos P., Moran M.A., Ferrer I., Baro A.M., Ávila J., Hernandez F., and Lucas J.J. Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J. Neurosci. 24 (2004) 9361-9371
55. Divry P. Etude histochimique des plaques seniles. J. Belge Neurol. Psychiatr. 27 (1927) 643-657
56. Eanes E.D., and Glenner G.G. X-ray diffraction studies of amyloid filaments. J. Histochem. Cytochem. 16 (1968) 673-677
57. Eikelenboom P., Bate C., Van Gool W.A., Hoozemans J.J., Rozemuller J.M., Veerhuis R., and Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia 40 (2002) 232-239
58. Emmerling M.R., Spiegel K., and Watson M.D. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. Immunopharmacology 38 (1997) 101-109
59. Fahn S., and Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1 (2004) 139-154
60. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., and Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 362 (1993) 543-546
61. Fraser P.E., Nguyen J.T., Chin D.T., and Kirschner D.A. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J. Neurochem. 59 (1992) 1531-1540
62. Gadjusek D.C. Kuru in the New Guinea highlands. In: Spillane J.D. (Ed). Tropical neurology (1973), Oxford Univ. Press, New York 377-383
63. Gellermann G.P., Ullrich K., Tannert A., Unger C., Habicht G., Sauter S.R., Hortschansky P., Horn U., Mollmann U., Decker M., Lehmann J., and Fandrich M. Alzheimer-like plaque formation by human macrophages is reduced by fibrillation inhibitors and Lovastatin. J. Mol. Biol. 360 (2006) 251-257
64. Gestwicki J.E., Crabtree G.R., and Graef I.A. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 306 (2004) 865-869
65. Giger M., Baumgartner H.R., and Zbinden G. Toxicological effects of Evans blue and Congo red on blood platelets. Agents Actions 4 (1974) 173-180
66. Glenner G.G., Eanes E.D., and Page D.L. The relation of the properties of Congo red-stained amyloid fibrils to the beta-conformation. J. Histochem. Cytochem. 20 (1972) 821-826
67. Gupta-Bansal R., and Brunden K.R. Congo red inhibits proteoglycan and serum amyloid P binding to amyloid beta fibrils. J. Neurochem. 70 (1998) 292-298
68. Hahon N. Inhibition of viral interferon induction in mammalian cell cultures by azo dyes and derivatives activated with rat liver S9 fraction. Environ. Res. 37 (1985) 228-238
69. Haley T.J. Benzidine revisited: a review of the literature and problems associated with the use of benzidine and its congeners. Clin. Toxicol. 8 (1975) 13-42
70. Harrison P.M., Bamborough P., Daggett V., Prusiner S.B., and Cohen F.E. The prion folding problem. Curr. Opin. Struct. Biol. 7 (1997) 53-59
71. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., and Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6739-6744
72. Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K., and Saido T.C. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 8 (2005) 527-533
73. Hirakura Y., Lin M.C., and Kagan B.L. Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo red. J. Neurosci. Res. 57 (1999) 458-466
74. Hirakura Y., Azimov R., Azimova R., and Kagan B.L. Polyglutamine-induced ion channels: a possible mechanism for the neurotoxicity of Huntington and other CAG repeat diseases. J. Neurosci. Res. 60 (2000) 490-494
75. Hoefert V.B., Aiken J.M., McKenzie D., and Johnson C.J. Labeling of the scrapie-associated prion protein in vitro and in vivo. Neurosci. Lett. 371 (2004) 176-180
76. Huang F.P., Farquhar C.F., Mabbott N.A., Bruce M.E., and MacPherson G.G. Migrating intestinal dendritic cells transport PrP(Sc) from the gut. J Gen Virol. 83 (2002) 267-271
77. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
78. Inestrosa N.C., Alvarez A., Perez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., and Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16 (1996) 881-891
79. Inestrosa N.C., Alvarez A., Dinamarca M.C., Perez-Acle T., and Colombres M. Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo red and the role of the Wnt pathway. Curr. Alzheimer Res. 2 (2005) 301-306
80. Ingrosso L., Ladogana A., and Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 69 (1995) 506-508
81. Ishii T., Haga S., Yagashita S., and Tateishi J. The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstman-Straussler-Scheinkel disease. Appl. Pathol. 2 (1984) 370-379
82. Ishii K., Klunk W.E., Arawaka S., Debnath M.L., Furiya Y., Sahara N., Shoji S., Tamaoka A., Pettegrew J.W., and Mori H. Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice. Neurosci. Lett. 333 (2002) 5-8
83. Ishikawa K., Doh-ura K., Kudo Y., Nishida N., Murakami-Kubo I., Ando Y., Sawada T., and Iwaki T. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 85 (2004) 1785-1790
84. Jellinger K.A. Neuropathological spectrum of synucleinopathies. Mod. Disord. Suppl. 6 (2003) S2-S12
85. Jin L.W., Claborn K.A., Kurimoto M., Geday M.A., Maezawa I., Sohraby F., Estrada M., Kaminksy W., and Kahr B. Imaging linear birefringence and dichroism in cerebral amyloid pathologies. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15294-15298
86. Junn E., Lee S.S., Suhr U.T., and Mouradian M.M. Parkin accumulation in aggresomes due to proteasome impairment. J. Biol. Chem. 277 (2002) 47870-47877
87. Kagan D.Z., and Rozinova V.N. Inhibition of amyloidogenesis with Congo red in experimental amyloidosis. Probl. Tuberk. 9 (1974) 72-74
88. Kagan B.L., Azimov R., and Azimova R. Amyloid peptide channels. J. Membr. Biol. 202 (2004) 1-10
89. Kanski J., Sultana R., Klunk W., and Butterfield D.A. Antioxidant activity of X-34 in synaptosomal and neuronal systems. Brain Res. 988 (2003) 173-179
90. Kaszuba J., Konieczny L., Piekarska B., Roteerman I., and Rybarska J. Bis-azo dyes interference with effector activation of antibodies. J. Physiol. Pharmacol. 44 (1993) 233-242
91. Kato M., Saito H., and Abe K. Nanomolar amyloid beta protein-induced inhibition of cellular redox activity in cultured astrocytes. J. Neurochem. 68 (1997) 1889-1895
92. Kelly J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6 (1996) 11-17
93. Khurana R., Uversky V.N., Nielsen L., and Fink A.L. Is Congo red an amyloid-specific dye?. J. Biol. Chem. 276 (2001) 22715-22721
94. Kim Y.S., Randolph T.W., Manning M.C., Stevens F.J., and Carpenter J.F. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J. Biol. Chem. 278 (2003) 10842-10850
95. Kisilevsky R., and Szarek W.A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1 (1995) 143-148
96. Kitamoto T., Muramoto T., Mohri S., Doh-Ura K., and Tateishi J. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J. Virol. 65 (1991) 6292-6295
97. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
98. Klunk W.E., Pettegrew J.W., and Abraham D.J. Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37 (1989) 1273-1281
99. Klunk W.E., Debnath M.L., and Pettegrew J.W. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol. Aging 15 (1994) 691-698
100. Klunk W.E., Debnath M.L., and Pettegrew J.W. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol. Aging 16 (1995) 541-548
101. Klunk W.E., Debnath M.L., Koros A.M., and Pettegrew J.W. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci. 63 (1998) 1807-1814
102. Klunk W.E., Bacskai B.J., Mathis C.A., Kajdasz S.T., McLellan M.E., Frosch M.P., Debnath M.L., Holt D.P., Wang Y., and Hyman B.T. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61 (2002) 797-805
103. 35) labeled Congo red dye. J. Nucl. Med. 1 (1960) 23-30
104. Kopec K.K., and Carroll R.T. Alzheimer's β-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J. Neurochem. 71 (1998) 2123-2131
105. Kourie J.I., and Culverson A. Prion peptide fragment PrP[106-126] forms distinct cation channel types. J. Neurosci. Res. 62 (2000) 120-133
106. Krebs M.R., Bromley E.H., and Donald A.M. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149 (2005) 30-37
107. Krol M., Roterman I., Piekarska B., Konieczny L., Rybarska J., Stopa B., and Spolnik P. Analysis of correlated domain motions in IgG light chain reveals possible mechanisms of immunological signal transduction. Proteins 59 (2005) 545-554
108. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
109. Kung M.P., Hou C., Zhuang Z.P., Skovronsky D.M., Zhang B., Gur T.L., Trojanowski J.Q., Lee V.M., and Kung H.F. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. J. Mol. Neurosci. 19 1-2 (2002) 7-10
110. Ladogana A., Casaccia P., Ingrosso L., Cibati M., Salvatore M., Xi Y.G., Masullo C., and Pocchiari M. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J. Gen. Virol. 73 (1992) 661-665
111. Landles C., and Bates G.P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep. 5 (2004) 958-963
112. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., and Lansbury Jr. P.T. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322 (2002) 1089-1102
113. Laszlo L., Lowe J., Self T., Kenward N., Landon M., McBride T., Farquhar C., McConnell I., Brown J., Hope J., and Mayer R.J. Lysosomes as key organelles in the pathogenesis of prion encephalopathies. J. Pathol. 166 (1992) 333-341
114. Lee V.M. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol. Aging 23 (2002) 1039-1042
115. Lee H.J., and Lee S.J. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277 (2002) 48976-48983
116. LeVine III H. Mechanism of A beta(1-40) fibril-induced fluorescence of (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene (K114). Biochemistry 44 (2005) 15937-15943
117. Liao L.L., Horwitz S.B., Huang M.T., Grollman A.P., Steward D., and Martin J. Triphenylmethane dyes as inhibitors of reverse transcriptase, ribonucleic acid polymerase, and protein synthesis. Structure-activity relationships. J. Med. Chem. 18 (1975) 117-120
118. Lin M.C., Mirzabekov T., and Kagan B.L. Channel formation by a neurotoxic prion protein fragment. J. Biol. Chem. 272 (1997) 44-47
119. Liu Y., and Piasecki D. A cell-based method for the detection of nanomolar concentrations of bioactive amyloid. Anal. Biochem. 289 (2001) 130-136
120. Liu Y., and Schubert D. Cytotoxic amyloid peptides inhibit cellular MTT reduction by enhancing MTT formazan. J. Neurochem. 69 (1997) 2285-2293
121. Liu Y., Peterson D., Kimura H., and Schubert D. The mechanism of cellular MTT reduction. J. Neurochem. 69 (1997) 581-593
122. Liu J., Tang M., Ruben M., and Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J. Mol. Cell. Cardiol. 37 (2005) 1097-1109
123. Lorenzo A., and Yankner B.A. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12243-12247
124. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
125. Masuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T., Hisanaga S.I., Goedert M., and Hasegawa M. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45 (2006) 6085-6094
126. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
127. Mautner H.G., Merrill R.E., Currier S.F., and Harvey G. Interaction of aromatic dyes wit the coenzyme A binding site of choline acetyltrasnferase. J. Med. Chem. 24 (1981) 1534-1537
128. McKinley M.P., Taraboulos A., Kenaga L., Serban D., Stieber A., Dearmond S.J., Prusiner S.B., and Gonatas N. Ultrastructural localization of scrapie prion proteins in cytoplastic vesicles of infected cultured cells. Lab. Invest. 65 (1991) 622-630
129. Mihara H., Takahashi Y., and Ueno A. Design of peptides undergoing self-catalytic alpha-to-beta transition and amyloidogenesis. Biopolymers 47 (1998) 83-92
130. Milhavet O., Mange A., Casanova D., and Lehmann S. Effect of Congo red on wild-type and mutated prion proteins in cultured cells. J. Neurochem. 74 (2000) 222-230
131. Mirzabekov T.A., Lin M.C., and Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271 (1996) 1988-1992
132. Mohan P., Singh R., Wepsiec J., Gonzalez I., Sun D.K., and Sarin P.S. Inhibition of HIV replication by naphthalenemonosulfonic acid derivatives and a bis naphthalenedisulfonic acid compound. Life Sci. 47 (1990) 993-999
133. Monoi H., Futaki S., Kugimiya S., Minakata H., and Yoshihara K. Poly-l-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys. J. 78 (2000) 2892-2899
134. Morton A.J., Lagan M.A., Skepper J.N., and Dunnett S.B. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J. Neurocytol. 29 (2000) 679-702
135. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
136. Muller W.E., Zahn R.K., and Seidel H.J. Inhibitors acting on nucleic acid synthesis in an oncogenic RNA virus. Nat. New Biol. 232 (1971) 143-145
137. Nakajima A., and Tanaka H. Evaluation of Congo red test for the function of the reticuloendothelial system. Tohoku J. Exp. Med. 79 (1963) 62-76
138. Naslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A.D., Tjernberg L.O., Silberring J., Gandy S.E., Winblad B., Greengard P., Nordstedt C., and Terenius L. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8378-8382
139. National Cancer Institute (NCI), Carcinogenesis Testing Program, 1978. 13-week subchronic toxicity studies of Direct Blue 6, Direct Black 38, and Direct Brown 95 dyes, Carcinogenesis Technical Report 108. US Government Printing Office, Washington, DC, U. S. A.
140. National Institute for Occupational Safety and Health (NIOSH), Center for Disease Control. 1980. Special hazard review of benzidine-based dyes, DHHS (NIOSH) Publication 80-109. National Institute for Occupational Safety and Health, Cincinnati. OH, U. S. A.
141. Ouchi E., Nomura N., Watabe S., Seiji K., Sato J., Gonai T., Miura K., and Yamagata S. Clinical significance of Congo red test. Tohoku J. Exp. Med. 118 (1976) 191-198 (Suppl.)
142. Pan K.M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R.J., Cohen F.E., and Prusiner S.B. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10962-10966
143. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
144. Pauling L., and Corey R.B. Configurations of polypeptide chains with favored orientations around single bonds: two new pleated sheets. Proc. Natl. Acad. Sci. U. S. A. 37 (1951) 729-740
145. Pauly P.C., and Harris D.A. Copper stimulates endocytosis of the prion protein. J. Biol. Chem. 273 (1998) 33107-33110
146. Piekarska B., Rybarska J., Stopa B., Zemanek G., Krol M., Roterman I., and Konieczny L. Supramolecularity creates nonstandard protein ligands. Acta Biochim. Pol. 46 (1999) 841-851
147. Piekarska B., Konieczny L., Rybarska J., Stopa B., Spolnik P., Roterman I., and Krol M. Intramolecular signaling in immunoglobulins-new evidence emerging from the use of supramolecular protein ligands. J. Physiol. Pharmacol. 55 (2004) 487-501
148. Podlisny M.B., Walsh D.M., Amarante P., Ostaszewski B.L., Stimson E.R., Maggio J.E., Teplow D.B., and Selkoe D.J. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37 (1998) 3602-3611
149. Poirier M.A., Li H., Macosko J., Cai S., Amzel M., and Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277 (2002) 41032-41037
150. Poli G., Ponti W., Carcassola G., Ceciliani F., Colombo L., Dall'Ara P., Gervasoni M., Giannino M.L., Martino P.A., Pollera C., Villa S., and Salmona M. In vitro evaluation of the anti-prionic activity of newly synthesized Congo red derivatives. Arzneim. Forsch. 53 (2003) 875-888
151. Poli G., Martino P.A., Villa S., Carcassola G., Giannino M.L., Dall'Ara P., Pollera C., lussich S., Tranquillo V.M., Bareggi S., Mantegazza P., and Ponti W. Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung 54 (2004) 406-415
152. Pollack S.J., Sadler I.I., Hawtin S.R., Tailor V.J., and Shearman M.S. Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci. Lett. 197 (1995) 211-214
153. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
154. Prusiner S.B. Molecular biology of prion diseases. Science 252 (1991) 1515-1522
155. Qin Z.H., and Gu Z.L. Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol. Sin. 25 (2004) 1243-1249
156. Rawal B.D., and Vyas G.N. Magnesium-mediated reversal of the apparent virucidal effect of ascorbic acid or Congo red reacted in vitro with the human immunodeficiency virus. Biologicals 24 (1996) 113-116
157. Rogers J., Cooper N.R., Webster S., Schulz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., and Lieberburg I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10016-10020
158. Roher A.E., Baudry J., Chaney M.O., Kuo Y.M., Stine W.B., and Emmerling M.R. Oligomerizaiton and fibril asssembly of the amyloid-beta protein. Biochim. Biophys. Acta 1502 (2000) 31-43
159. Romhanyi G. Selective differentiation between amyloid and connective tissue structures based on the collagen specific topooptical staining reaction with Congo red. Virchows Arch., A. 354 (1971) 209-222
160. Roterman I., Krol M., Nowak M., Konieczny L., Rybarska J., Stopa B., Piekarska B., and Zemanek G. Why Congo red binding is specific for amyloid proteins-model studies and a computer analysis approach. Med. Sci. Monit. 7 (2001) 771-784
161. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?. Neuron 19 (1997) 1147-1150
162. Rozemuller J.M., Eikelenboom P., Pals S.T., and Stam F.C. Microglial cells around plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101 (1989) 288-292
163. Rudyk H., Vasiljevic S., Hennion R.M., Birkett C.R., Hope J., and Gilbert I.H. Screening Congo red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J. Gen. Virol. 81 (2000) 1155-1164
164. Rudyk H., Knaggs M.H., Vasiljevic S., Hope J., Birkett C., and Gilbert I.H. Synthesis and evaluation of analogues of Congo red as potential compounds against transmissible spongiform encephalopathies. Eur. J. Med. Chem. 38 (2003) 567-579
165. Rybarska J., Piekarska B., Stopa B., Spolnik P., Zemanek G., Konieczny L., and Roterman I. In vivo accumulation of self-assembling dye Congo red in an area marked by specific immune complexes: possible relevance to chemotherapy. Folia Histochem. Cytobiol. 42 (2004) 101-110
166. Sadler I.I., Smith D.W., Shearman M.S., Ragan C.I., Tailor V.J., and Pollack S.J. Sulphated compounds attenuate β-amyloid toxicity by inhibiting its association with cells. NeuroReport 7 (1995) 49-53
167. Sadowski M., Pankiewicz J., Scholtzova H., Tsai J., Li Y., Carp R.I., Meeker H.C., Gambetti P., Debnath M., Mathis C.A., Shao L., Gan W.B., Klunk W.E., and Wisniewski T. Targeting prion amyloid deposits in vivo. J. Neuropathol. Exp. Neurol. 63 (2004) 775-784
168. Salemme F.R. Structural properties of protein β-sheets. Prog. Biophys. Mol. Biol. 42 (1983) 95-133
169. Sanchez I., Mahlke C., and Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
170. Sato K., Higuchi M., Iwata N., Saido T.C., and Sasamoto K. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur. J. Med. Chem. 39 (2004) 573-578
171. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., and Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90 (1997) 549-558
172. Schmidt M.L., Schuck T., Sheridan S., Kung M.P., Kung H., Zhuang Z.P., Bergeron C., Lamarche J.S., Skovronsky D., Giasson B.I., Lee V.M., and Trojanowski J.Q. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am. J. Pathol. 159 (2001) 937-943
173. Sellarajah S., Lekishvili T., Bowring C., Thompsett A.R., Rudyk H., Birkett C.R., Brown D.R., and Gilbert I.H. Synthesis of analogues of Congo red and evaluation of their anti-prion activity. J. Med. Chem. 47 (2004) 5515-5534
174. Sereikaite J., and Bumelis V.A. Congo red interaction with alpha-proteins. Acta Biochim. Pol. 53 (2006) 87-92
175. Shaffer L.M., Dority M.D., Gupta-Bansal R., Frederickson R.C.A., Younkin S.G., and Brunden K.R. Amyloid β protein (Aβ) removal by neuroglial cells in culture. Neurobiol. Aging 16 (1995) 737-745
176. Shearman M.S., Ragan C.I., and Iversen L.L. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of, β-amyloid-mediated cell death. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1470-1474
177. Shen Z.X. Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease. Med. Hypotheses 63 (2004) 308-321
178. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., and Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
179. Shin H.J., Lee E.K., Lee J.H., Lee D., Chang C.S., Kim Y.S., and Paik S.R. Eosin interaction of alpha-synuclein leading to protein self-oligomerization. Biochim. Biophys. Acta 1481 (2000) 139-146
180. Shirhama T., Cohen A.S., and Rodgers O.G. Phagocytosis of amyloid: in vitro interaction of mouse peritoneal macrphages with human amyloid fibrils and their accelerated uptake after dye binding. Exp. Mol. Pathol. 14 (1971) 10-23
181. Shyng S.L., Lehmann S., Moulder K.L., and Harris D.A. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J. Biol. Chem. 270 (1995) 30221-30229
182. Skovronsky D.M., Zhang B., Kung M.P., Kung H.F., Trojanowski J.Q., and Lee V.M. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7609-7614
183. Skowronek M., Roterman I., Konieczny L., Stopa B., Rybarska J., Piekarska B., Gorecki A., and Krol M. The conformational characteristics of Congo red, Evans blue and Trypan blue. Comput. Chem. 24 (2000) 429-450
184. Smith T.M., and Squires R.F. Differential inhibition of brain specific [3H]flunitrazepam binding by several types of dyes. Neurochem. Res. 8 (1983) 1177-1183
185. Smith D.L., Portier R., Woodman B., Hockly E., Mahal A., Klunk W.E., Li X.J., Wanker E., Murray K.D., and Bates G.P. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol. Dis. 8 (2001) 1017-1026
186. Snow A.D., Mar H., Nochlin D., Kimata K., Kato M., Suzuki S., Hassell J., and Wight T.N. The presence of heparan sulfate proteoglycans in the neurtic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Pathol. 133 (1988) 456-463
187. Snow A.D., Kisilevsky R., Willmer J., Prusiner S.B., and DeArmond S.J. Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol. (Berl.) 77 (1989) 337-342
188. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
189. Steensma D.P. "Congo" red: out of Africa?. Arch. Pathol. Lab. Med. 125 (2001) 250-252
190. Stopa B., Gorny M., Konieczny L., Piekarska B., Rybarska J., Skowronek M., and Roterman I. Supramolecular ligands: monomer structure and protein ligation capability. Biochimie 80 (1998) 963-968
191. Stopa B., Piekarska B., Konieczny L., Rybarska J., Spolnik P., Zemanek G., Roterman I., and Krol M. The structure and protein binding of amyloid-specific dye reagents. Acta Biochim. Pol. 50 (2003) 1213-1227
192. Styren S.D., Hamilton R.L., Styren G.C., and Klunk W.E. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J. Histochem. Cytochem. 48 (2000) 1223-1232
193. Termine J.D., Eanes E.D., Ein D., and Glenner G.G. Infrared spectroscopy of human amyloid fibrils and immunoglobulin proteins. Biopolymers 11 (1972) 1103-1113
194. Tschopp T.B., Baumgartner H.R., and Studer A. Effect of Congo red on blood platelets and leucocytes of rabbits and cats. Thromb. Diath. Haemorrh. 26 (1971) 488-492
195. Tubis M., Blahd W.H., and Nordyke R.A. The preparation and use of radioiodinated Congo red in detecting amyloidosis. J. Am. Pharm. Assoc. Am. Pharm. Assoc. 49 (1960) 422-425
196. Turnell W.G., and Finch J.T. Binding of the dye Congo red to the amyloid protein pig insulin reveals a novel homology amongst amyloid-forming peptide sequences. J. Mol. Biol. 227 (1992) 1205-1223
197. Unterberger U., Voigtländer T., and Budka H. Pathogenesis of prion diseases. Acta Neuropathol. 109 (2005) 32-48
198. van Keulen L.J., Schreuder B.E., Meloen R.H., Mooij-Harkes G., Vromans M.E., and Langeveld J.P. Immunohistochemical detection of prion protein in lymphoid tissues of sheep with natural scrapie. J. Clin. Microbiol. 34 (1996) 1228-1231
199. Villa S., Cignarella G., Barlocco D., Gervasoni M., Carcassola G., Giannino L., and Mantegazza P. Congo red analogues as potential anti-prion agents. Farmaco 58 (2003) 929-937
200. Vogt W., Rhl H., Wagner B., and Diamantstein T. Stimulation of DNA synthesis in mouse lymphoid cells by polyanions in vitro: II. Relationship between adjuvant activity and stimulation of DNA synthesis by polyanions. Eur. J. Immunol. 3 (1973) 493-496
201. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., and Lansbury Jr. P.T. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
202. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
203. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., and Richardson Jr. E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44 (1985) 559-577
204. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
205. Wells G.A., Dawson M., Hawkins S.A., Green R.B., Dexter I., Francis M.E., Simmons M.M., Austin A.R., and Horigan M.W. Infectivity in the ileum of cattle challenged orally with bovine spongiform encephalopathy. Vet. Rec. 135 (1994) 40-41
206. Wilquet V., and De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr. Opin. Neurobiol. 14 (2004) 582-588
207. Woody R.M. Circular dichroism of peptides. In: Hruby V.J. (Ed). The Peptides vol. 7 (1985), Academic Press, New York 15-115
208. Woody A.Y., Reisbig R.R., and Woody R.W. Spectroscopic studies of Congo red binding to RNA polymerase. Biochim. Biophys. Acta 655 (1981) 82-88
209. Wu C., Pike V.W., and Wang Y. Amyloid imaging: from benchtop to bedside. Curr. Top. Dev. Biol. 70 (2005) 171-213
210. Yamamoto A., Lucas J.J., and Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntingtonís disease. Cell 101 (2000) 57-66
211. Young I.D., Willmer J.P., and Kisilevsky R. The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis. Acta Neuropathol. 78 (1989) 202-209
212. Zemanek G., Rybarska J., Stopa B., Piekarska B., Spolnik P., Konieczny L., Roterman I., and Bugajski A. Protein distorsion-derived mechanism of signal discrimination in monocytes revealed using Congo red to stain activated cells. Folia Histochem. Cytobiol. 41 (2003) 113-124
213. Zenser T.V., Lakshmi V.M., and Davis B.B. N-glucuronidation of benzidine and its metabolites. Role in bladder cancer. Drug Metab. Dispos. 26 (1998) 856-859
214. Zhen W., Han H., Anguiano M., Lemere C.A., Cho C.G., and Lansbury P.T. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. J. Med. Chem. 42 (1999) 2805-2815